Publications by authors named "Daniel Rauh"

Claim this Profile
P
Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial).
Johanna Falkenhorst, Philipp Ivanyi, Tom Schulz, Rainer Hamacher, Bernd Kasper, Daniel Rauh

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting KRAS with cyclic linker based inhibitors to explore warhead orientation.
Tonia Kirschner, João Rodriguez, Emerson Gonçalves Moreira, Janina Niggenaber, Jonas D Warmuth, Daniel Rauh

Sci Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational Design of Lysine Targeting Covalent Binders Using Rosetta.
Barr Tivon, Jan Wiese, Matthias P Müller, Ronen Gabizon, Daniel Rauh

J Chem Inf Model· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing TET Inhibitor Development: From Structural Insights to Biological Evaluation.
Suzanne Willems, Lejla Maksumic, Janina Niggenaber, Tzu-Chen Lin, Tom Schulz, Daniel Rauh

ACS Med Chem Lett· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors─Exploring Their Potential in Targeting GIST.
Tom Schulz, Rajesh Gontla, Alina Teuber, Maria Beerbaum, Benjamin S Fletcher, Daniel Rauh

J Med Chem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Y. Xia et al.
Sebastian Bauer, Jonathan A Fletcher, Daniel Rauh, Johanna Falkenhorst, Thomas Mühlenberg

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.
Thomas Mühlenberg, Johanna Falkenhorst, Tom Schulz, Benjamin S Fletcher, Alina Teuber, Daniel Rauh

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises.
Kosmas Alexandros Pervanidis, Giovanni Danilo D'Angelo, Jörn Weisner, Sven Brandherm, Daniel Rauh

J Med Chem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
Tonia Kirschner, Matthias P Müller, Daniel Rauh

J Med Chem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A high-throughput effector screen identifies a novel small molecule scaffold for inhibition of ten-eleven translocation dioxygenase 2.
Shubhendu Palei, Jörn Weisner, Melina Vogt, Rajesh Gontla, Benjamin Buchmuller, Daniel Rauh

RSC Med Chem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragtory: Pharmacophore-Focused Design, Synthesis, and Evaluation of an sp-Enriched Fragment Library.
Mike Bührmann, Shivakrishna Kallepu, Jonas D Warmuth, Jan N Wiese, Christiane Ehrt, Daniel Rauh

J Med Chem· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines.
Tobias Grabe, Kirujan Jeyakumar, Janina Niggenaber, Tom Schulz, Sandra Koska, Daniel Rauh

ACS Med Chem Lett· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into the Conformational Plasticity of the Protein Kinase Akt1 by Multi-Lateral Dipolar Spectroscopy.
Juliane Stehle, Jörn Weisner, Leanne Eichhorn, Daniel Rauh, Malte Drescher

Chemistry· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.
Luiza Martins Nascentes Melo, Dayana Herrera-Rios, Daniel Hinze, Stefanie Löffek, Irem Oezel, Daniel Rauh

J Immunother Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors.
Lisa Goebel, Tonia Kirschner, Sandra Koska, Amrita Rai, Petra Janning, Daniel Rauh

Elife· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma.
Irina Heid, Corinna Münch, Sinan Karakaya, Smiths S Lueong, Alina M Winkelkotte, Daniel Rauh

Cancer Metab· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A high-throughput effector screen identifies a novel small molecule scaffold for inhibition of ten-eleven translocation dioxygenase 2.
Shubhendu Palei, Jörn Weisner, Melina Vogt, Rajesh Gontla, Benjamin Buchmuller, Daniel Rauh

RSC Med Chem· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Covalent MKK7 Inhibitors Crude Nanomole-Scale Libraries.
Paul Gehrtz, Shir Marom, Mike Bührmann, Julia Hardick, Silke Kleinbölting, Daniel Rauh

J Med Chem· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persister state-directed transitioning and vulnerability in melanoma.
Heike Chauvistré, Batool Shannan, Sheena M Daignault-Mill, Robert J Ju, Daniel Picard, Daniel Rauh

Nat Commun· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of Nrf2-derived hydrocarbon stapled peptides for the disruption of protein-DNA-interactions.
Bianca Wiedemann, Dominic Kamps, Laura Depta, Jörn Weisner, Jana Cvetreznik, Daniel Rauh

PLoS One· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Covalent Allosteric Inhibitors of Akt Generated Using a Click Fragment Approach.
Leandi van der Westhuizen, Jörn Weisner, Abu Taher, Ina Landel, Lena Quambusch, Daniel Rauh

ChemMedChem· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors.
Jonas Lategahn, Hannah L Tumbrink, Carsten Schultz-Fademrecht, Alena Heimsoeth, Lisa Werr, Daniel Rauh

J Med Chem· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular model system to dissect the isoform-selectivity of Akt inhibitors.
Lena Quambusch, Laura Depta, Ina Landel, Melissa Lubeck, Tonia Kirschner, Daniel Rauh

Nat Commun· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands.
Janina Niggenaber, Leonie Heyden, Tobias Grabe, Matthias P Müller, Jonas Lategahn, Daniel Rauh

ACS Med Chem Lett· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRasG12C inhibitors in clinical trials: a short historical perspective.
Lisa Goebel, Matthias P Müller, Roger S Goody, Daniel Rauh

RSC Med Chem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis